1 / 3

Rituximab as Maintenance Therapy for Patients with Follicular Lymphona: Overall Survival

Rituximab as Maintenance Therapy for Patients with Follicular Lymphona: Overall Survival. 0.1. 0.2. 0.5. 1.0. 2.0. 5.0. 10.0. Favours rituximab. Favours control. OR=odds ratio. Adapted from Vidal et al. ASH 2007, abstract 3408. Dense-R-CHOP-14 Trial Survival Results. Percentage.

eagan-thomas
Télécharger la présentation

Rituximab as Maintenance Therapy for Patients with Follicular Lymphona: Overall Survival

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Rituximab as Maintenance Therapy for Patients with Follicular Lymphona: Overall Survival 0.1 0.2 0.5 1.0 2.0 5.0 10.0 Favours rituximab Favours control OR=odds ratio Adapted from Vidal et al. ASH 2007, abstract 3408.

  2. Dense-R-CHOP-14 Trial Survival Results Percentage Poor prognosis (aaIPI 3-5) Adapted from Pfreundschuh et al. ASH 2007, abstract 789.

  3. R-FCM in CLL: Response Rates Near PR Complete Response MRD-positive CR PR Grade 3 or 4 neutropenias 0 10 20 30 40 50 60 70 80 90 100 OR 92%; grade 3/4 neurtropenia 8%. Adapted from Bosch et al. ASH 2007, abstract 626.

More Related